Gene therapy vectors based on adeno-associated virus type 1.
about
Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectorsAdeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificityIntramuscular viral delivery of paraplegin rescues peripheral axonopathy in a model of hereditary spastic paraplegiaNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapyAAV-mediated liver-specific MPV17 expression restores mtDNA levels and prevents diet-induced liver failureCross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroupsAdeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene TransferRapid, long-term labeling of cells in the developing and adult rodent visual cortex using double-stranded adeno-associated viral vectors.Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transferDesigner gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transferRecombination and population mosaic of a multifunctional viral gene, adeno-associated virus cap.Different tropism of adenoviruses and adeno-associated viruses to corneal cells: implications for corneal gene therapyComparative study of the transfection efficiency of commonly used viral vectors in rhesus monkey (Macaca mulatta) brainsComplete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.AAV's anatomy: roadmap for optimizing vectors for translational successA simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cellsHost and vector-dependent effects on the risk of germline transmission of AAV vectors.Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established diseaseStable secondary structure near the nicking site for adeno-associated virus type 2 Rep proteins on human chromosome 19Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypesAdeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer.Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons.Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuriaEvolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvovirusesAmelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin.Systemic gene transfer reveals distinctive muscle transduction profile of tyrosine mutant AAV-1, -6, and -9 in neonatal dogs.Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.Molecular characterization of adeno-associated viruses infecting childrenGene transfer in the liver using recombinant adeno-associated virusCloning and characterization of a bovine adeno-associated virus.Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization propertiesLiver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype.Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size.Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis.Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vectorCharacterization of the transcription profile of adeno-associated virus type 5 reveals a number of unique features compared to previously characterized adeno-associated virusesTransduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats.
P2860
Q24529153-3B4C7665-F24F-4C2F-9031-6BCA563BD207Q24529161-94DCECA3-B505-478D-99CB-7EDF336B60CCQ24534210-B5BB9A3B-55E3-4233-9202-84CE0BA67DBDQ24535690-FC4A832E-A49D-47DD-8364-C26EEAF22256Q24622009-6294F33D-5D73-4046-846C-FE18B6649AEBQ24623923-F73ED7DE-8545-42A0-BB8C-FBB28E356B10Q24634560-F48E9EF6-B8B4-44CF-B553-CCB228F777E4Q27678476-1E044F8F-6361-45C7-915E-D4261DB9BE8AQ27681034-D843122B-F212-4EEE-A991-3F94883DAA9AQ30152887-4DD1877E-14FE-4F9B-90B9-7D2D99A5E50BQ30495536-397F2815-413E-4D88-B120-B7B1EF7365E5Q30498316-6EE16C68-495E-48AF-84CD-C649A8EF7ABBQ33296224-5A3FFAF9-FD37-4F5F-8198-819227CD69DEQ33320533-4C5F9610-FD64-4209-AC7F-B83A0B4323CAQ33386030-0B8400AC-1DB7-477B-A3A5-7C03C65BDB22Q33577391-B5ED5293-882F-4B4E-9ABE-A79DCB960227Q33617709-4B140DFA-7337-4BF6-A4C1-FF814CFAD6DDQ33659389-16E73FD5-FF40-46A1-A6FF-C25E55826E14Q33713203-BB1DBE6B-C6DB-4B0A-818B-79E32D3F018AQ33713716-52C36B91-F76F-4E43-898E-4C336CFF4DEEQ33731154-EF93DA78-993B-4668-8B8C-EE129ADA0A1BQ33737816-108FFE5E-B485-4A40-B956-4AE0CC4BB6B5Q33793801-53DF9BAC-7039-494B-ADC7-4D9DC4F5178DQ33802811-91D966B2-BF92-488A-B2AC-39B2A6A22095Q33822237-0072A677-4ED1-4A22-BD72-01D78DCAC8DDQ33832790-B5891624-1F7A-418A-B6BD-D754C8710FA2Q33865608-A2D3615D-F512-452D-B48F-ECA067F66C56Q33922811-093D1C53-DC93-49E6-BDC3-16B8A4913E60Q34001776-2A16F01D-154A-4827-BA10-8D1A18ACF4D2Q34069571-29AA50E5-5A1C-44A1-A96C-F5EC379ECE78Q34142840-22C544E9-500B-475C-B533-809FAA288A9CQ34164885-788D95E1-A162-4362-B51A-9B055A4E019DQ34192972-2C096F0B-6B91-41FC-AEB1-5F40DD3C863BQ34228552-04481CA0-2DD0-4684-A835-FE366361912FQ34233154-72420967-E507-4B9B-98B0-BBA88FBA0C1BQ34342913-CE3E8426-0170-4747-B003-69250D94B7BEQ34348149-CBE35EE8-80A7-4064-A8A2-9A77533955DAQ34348760-FCDEBBEB-A1B8-459E-AD6E-171C909882A1Q34353746-C383088A-AB94-41CC-8CAE-863E717D299CQ34436780-161BD0A0-3EA6-45A1-A8CA-617D1ECC6BC2
P2860
Gene therapy vectors based on adeno-associated virus type 1.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Gene therapy vectors based on adeno-associated virus type 1.
@en
Gene therapy vectors based on adeno-associated virus type 1.
@nl
type
label
Gene therapy vectors based on adeno-associated virus type 1.
@en
Gene therapy vectors based on adeno-associated virus type 1.
@nl
prefLabel
Gene therapy vectors based on adeno-associated virus type 1.
@en
Gene therapy vectors based on adeno-associated virus type 1.
@nl
P2093
P2860
P1433
P1476
Gene therapy vectors based on adeno-associated virus type 1.
@en
P2093
P2860
P304
P407
P577
1999-05-01T00:00:00Z